Pierre Fabre Medicament

This study tested a new combination of drugs (encorafenib and cetuximab) against standard treatments in 107 Chinese patients with a specific genetic mutation (BRAF V600E) causing metastatic colorectal cancer. The goal was to see if the new combo could slow cancer growth better th…

This study looked back at medical records of 274 people with a specific type of advanced colon cancer (BRAF V600E mutation) to see which treatments doctors used first and how well they worked. Since there is no standard targeted therapy for this cancer, the goal was to understand…

This study observed about 400 adults with advanced BRAF-mutant melanoma who were taking targeted therapy (BRAF/MEK inhibitors) and using a smartphone app called TavieSkin. The goal was to describe patient characteristics, how they used the app, and their quality of life. No new t…

This study reviewed medical records of 111 adults with early-stage HER2-positive breast cancer who received the drug neratinib as extra treatment after their main therapy, through a special early access program in Europe. The goal was to describe the patients' ages, genders, heal…

This study measured how skin problems caused by hormone therapy affect the daily lives of 155 women with early breast cancer. Participants, who had been on hormone therapy for 2-3 years, filled out questionnaires about their skin symptoms and quality of life. The goal was to bett…